NTRB Nasdaq Orthopedic, Prosthetic & Surgical Appliances & Supplies Financials FY2017βFY2026
NutriBand Inc. had $2.0M of revenue in fiscal 2026, down 4.8% on the year before. Over five years, revenue changed +16.6% a year on average.
Last close Β· Oct 23, 2026
$5.76
0.9%Hi! I read NutriBand Inc.βs latest annual report (fiscal 2026). Here is what stands out:
Good So-so Weak
Are sales growing?
β4.8%
No. Sales fell 4.8% last year.
Does it make a profit?
β404.1%
No. It lost money last year.
Does profit turn into cash?
β252.4%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days NutriBand Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
December 9, 2026
Wednesday Β· in 44 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Sep 4, 2026 | Q2 '27 | After the market closes | 10-Q β |
| Jun 11, 2026 | Q1 '27 | After the market closes | 10-Q β |
| Apr 29, 2026 | Q4 '26 | After the market closes | 10-K β |
| Dec 11, 2025 | Q3 '26 | Time not announced | 10-Q β |
| Sep 9, 2025 | Q2 '26 | After the market closes | 10-Q β |
| May 30, 2025 | Q1 '26 | After the market closes | 10-Q β |
| Apr 28, 2025 | Q4 '25 | After the market closes | 10-K β |
| Dec 4, 2024 | Q3 '25 | Time not announced | 10-Q β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· NutriBand Inc. had $2.0M of revenue in fiscal 2026, down 4.8% on the year before. Over five years, revenue changed +16.6% a year on average. Its operating margin was β408.4%, up 72.3Β pts: of every 100 in sales, about β408 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· NutriBand Inc. lost $8.2M in fiscal 2026.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$5.1M in fiscal 2026, β252.4% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably NutriBand Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | $4.9M | $2.0M | $0.5M | $4.3M | $4.6M |
| Debt incl. finance leases | β | β | $2.0M | β | β |
| Debt / equity | β | β | 0.3x | β | β |
| Interest coverage | β51.6x | β539.2x | β64.3x | β480.6x | β369.7x |
| Current ratio | 7.0x | 3.6x | 1.0x | 4.9x | 6.4x |
| Quick ratio | 6.8x | 3.3x | 0.9x | 4.7x | 6.2x |
| Total assets | $12.7M | $9.5M | $7.5M | $7.5M | $7.5M |
| Total liabilities | $0.9M | $0.9M | $1.1M | $1.0M | $0.9M |
| Shareholders' equity | $11.9M | $8.6M | $6.4M | $6.4M | $6.7M |
| Net debt (β = net cash) | β | β | $1.5M | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· NutriBand Inc. passes 3 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 4 / 7 | 4 / 7 | 1 / 8 | 5 / 8 | 4 / 8 | 3 / 8 | 4 / 8 | 3 / 8 | 3 / 8 |
| Accruals ratio | β9.0% | β2,545.9% | β149.8% | β73.0% | β43.5% | β29.7% | β13.5% | β23.1% | β78.1% | β41.2% |
| Altman Z'' | β36.64 | β157.44 | β8.45 | β25.04 | β4.48 | 8.72 | 0.60 | β10.20 | β16.21 | β15.84 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | β | β | $0.2M | $0.1M | $0.9M | $1.4M | $2.1M | $2.1M | $2.1M | $2.0M |
| Gross profit | β | β | β$0.0M | β$0.4M | $0.3M | $0.6M | $0.8M | $0.9M | $0.7M | $0.6M |
| Research and development | β | β | β | β | β | $0.4M | $1.0M | $2.0M | $3.1M | $1.9M |
| Operating income | β$0.2M | β$2.7M | β$3.3M | β$2.0M | β$2.6M | β$6.1M | β$4.5M | β$4.9M | β$10.3M | β$8.3M |
| Interest expense | β | β | β | $0.1M | $0.3M | $0.1M | $0.0M | $0.1M | $0.0M | $0.0M |
| Pretax income | β | β$2.7M | β$3.3M | β$2.7M | β$2.9M | β$6.2M | β$4.5M | β$5.5M | β$10.5M | β$8.2M |
| Net income | β$0.2M | β$2.7M | β$3.3M | β$2.7M | β$2.9M | β$6.2M | β$4.5M | β$5.5M | β$10.5M | β$8.2M |
| Net income to common | β | β | β | β | β | β$6.4M | β$4.5M | β | β$10.5M | β$30.0M |
| Diluted EPS | β$0.01 | β$0.14 | β$0.62 | β$0.50 | β$0.51 | β$0.80 | β$0.53 | β$0.69 | β$0.99 | β$2.58 |
| Diluted shares | 0.02B | 0.02B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B |
| Cash flow | ||||||||||
| Cash from operations | β$0.1M | β$0.1M | β$1.1M | β$0.9M | β$0.3M | β$2.8M | β$3.0M | β$3.5M | β$4.6M | β$5.1M |
| Capital expenditure | β | β | $0.0M | β | β | $0.1M | $0.1M | $0.1M | $0.1M | $0.0M |
| Free cash flow | β | β | β$1.1M | β | β | β$2.9M | β$3.1M | β$3.6M | β$4.7M | β$5.1M |
| Depreciation and amortization | β | $0.0M | $0.0M | $0.1M | $0.2M | $0.3M | $0.3M | $0.3M | $0.3M | $0.2M |
| Stock-based compensation | $0.0M | β | $1.8M | $0.3M | $2.0M | $0.4M | $0.7M | $0.5M | $1.4M | $2.6M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $0.0M | β | $0.5M | $0.0M | $0.2M | $4.9M | $2.0M | $0.5M | $4.3M | $4.6M |
| Total debt | $0.0M | $0.0M | $0.0M | β | β | β | β | $2.0M | β | β |
| Loans, net | β | β | β | β | β | $0.1M | β | β | β | β |
| Deposits | β | β | β | β | β | $0.3M | $0.3M | β | β | β |
| Current assets | $0.0M | $0.2M | $0.6M | $0.0M | $0.3M | $5.5M | $2.7M | $1.0M | $4.8M | $5.0M |
| Current liabilities | $0.0M | $0.0M | $0.4M | $2.0M | $2.6M | $0.8M | $0.7M | $1.0M | $1.0M | $0.8M |
| Inventory | $0.0M | $0.0M | β | β | $0.1M | $0.1M | $0.2M | $0.2M | $0.2M | $0.1M |
| Property and equipment, net | β | $0.1M | $0.1M | $0.1M | $1.1M | $1.0M | $0.9M | $0.8M | $0.7M | $0.6M |
| Goodwill | β | β | $1.7M | $1.7M | $7.5M | $5.3M | $5.0M | $5.0M | $1.7M | $1.7M |
| Intangible assets | β | β | $0.3M | $0.3M | $1.0M | $0.9M | $0.8M | $0.7M | $0.3M | $0.2M |
| Total assets | $0.0M | $0.2M | $2.8M | $2.2M | $9.9M | $12.7M | $9.5M | $7.5M | $7.5M | $7.5M |
| Total liabilities | $0.0M | $0.0M | $0.4M | $2.0M | $2.8M | $0.9M | $0.9M | $1.1M | $1.0M | $0.9M |
| Preferred stock | β | β | β | β | β | β | β | β | β | $0.0M |
| Shareholders' equity | $0.0M | $0.1M | $2.4M | $0.2M | $7.1M | $11.9M | $8.6M | $6.4M | $6.4M | $6.7M |
| Margins | ||||||||||
| Gross margin | β | β | β17.5% | β359.9% | 33.5% | 39.0% | 36.1% | 41.3% | 34.7% | 27.8% |
| Operating margin | β | β | β1,358.0% | β1,649.4% | β275.1% | β429.7% | β215.2% | β233.6% | β480.7% | β408.4% |
| EBITDA margin | β | β | β1,342.9% | β1,588.9% | β258.1% | β408.0% | β199.3% | β219.8% | β467.4% | β398.9% |
| Net margin | β | β | β1,358.0% | β2,279.4% | β310.8% | β434.3% | β215.6% | β263.0% | β490.0% | β404.1% |
| FCF margin | β | β | β452.4% | β | β | β203.3% | β147.5% | β171.6% | β220.5% | β252.4% |
| Returns | ||||||||||
| Return on capital | β1,838.9% | β | β136.4% | β | β | β | β | β48.4% | β | β |
| Return on capital employed | β655.0% | β2,199.1% | β138.5% | β1,122.2% | β35.3% | β51.1% | β51.4% | β74.7% | β158.5% | β123.0% |
| Return on equity | β655.0% | β3,695.6% | β263.7% | β211.0% | β80.5% | β65.1% | β43.9% | β73.1% | β162.9% | β125.6% |
| Return on assets | β401.3% | β2,637.6% | β224.1% | β108.7% | β48.4% | β54.5% | β40.4% | β64.6% | β139.9% | β109.6% |
| Return on tangible equity | β655.0% | β2,199.1% | β855.9% | β | β | β114.1% | β161.8% | β732.2% | β235.7% | β631.2% |
| Growth | ||||||||||
| Revenue growth | β | β | β | β51.3% | 690.4% | 50.7% | 46.2% | 0.3% | 2.6% | β4.8% |
| Share count change | β | β9.4% | β72.1% | 1.3% | 6.4% | 37.5% | 6.6% | β6.0% | 33.4% | 9.7% |
| Financial health | ||||||||||
| Debt / equity | 0.5x | 0.1x | 0.0x | β | β | β | β | 0.3x | β | β |
| Interest coverage | β | β | β | β26.8x | β9.2x | β51.6x | β539.2x | β64.3x | β480.6x | β369.7x |
| Current ratio | 2.6x | 3.8x | 1.5x | 0.0x | 0.1x | 7.0x | 3.6x | 1.0x | 4.9x | 6.4x |
| Quick ratio | 2.0x | 3.7x | 1.5x | 0.0x | 0.1x | 6.8x | 3.3x | 0.9x | 4.7x | 6.2x |
| Loans / deposits | β | β | β | β | β | 48.6% | β | β | β | β |
| Capital allocation | ||||||||||
| Capex / revenue | β | β | 1.7% | β | β | 5.7% | 3.8% | 2.5% | 4.3% | 0.3% |
| Stock comp / revenue | β | β | 719.1% | 211.6% | 212.5% | 25.7% | 35.2% | 24.0% | 65.9% | 129.3% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 4.0 | 4.0 | 1.0 | 5.0 | 4.0 | 3.0 | 4.0 | 3.0 | 3.0 |
| Altman Z'' | β36.6 | β157.4 | β8.4 | β25.0 | β4.5 | 8.7 | 0.6 | β10.2 | β16.2 | β15.8 |
| Accruals ratio | β9.0% | β2,545.9% | β149.8% | β73.0% | β43.5% | β29.7% | β13.5% | β23.1% | β78.1% | β41.2% |
Source: SEC EDGAR XBRL filings (CIK 0001676047). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
